Sugi Predict

Sugi Predict / Compounds / SCHEMBL8302605

SCHEMBL8302605

SCHEMBL8302605

Nc1ccc(-c2ccccn2)cc1[N+](=O)[O-]

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 8/20 0.62
▸ TDP1 Q9NUW8 3/20 0.62
▸ MEN1 O00255 2/20 0.62
▸ KMT2A Q03164 2/20 0.62
▸ POLB P06746 1/20 0.62
▸ NPSR1 Q6W5P4 1/20 0.52
▸ NPC1 O15118 3/20 0.49
▸ RAB9A P51151 3/20 0.49
▸ ALDH1A1 P00352 2/20 0.49
▸ CYP3A4 P08684 1/20 0.49
▸ ALOX15 P16050 1/20 0.49
▸ TLR4 O00206 1/20 0.48
▸ TLR2 O60603 1/20 0.48
▸ GPR35 Q9HC97 1/20 0.47
▸ TSHR P16473 1/20 0.46
▸ LMNA P02545 2/20 0.43
▸ PIK3CD O00329 1/20 0.43
▸ PIK3CA P42336 1/20 0.43
▸ PI4KA P42356 1/20 0.43
▸ PIK3CG P48736 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13736898 0.88 MAPT (0.49) MAPTTDP1MEN1KMT2APOLB
SCHEMBL12643379 0.82 MAPT (0.69) MAPTTDP1MEN1KMT2APOLB
SCHEMBL3031212 0.82 MAPT (0.63) MAPTMEN1KMT2ANPC1RAB9A
SCHEMBL6974757 0.82 AURKB (0.50) MAPTTDP1MEN1KMT2ANPC1
SCHEMBL6503392 0.82 MAPT (0.49) MAPTTDP1MEN1KMT2APOLB
SCHEMBL11235826 0.81 CHEK2 (0.50) MAPTTDP1MEN1KMT2APOLB
SCHEMBL1237443 0.79 TLR4 (0.49) MAPTPOLBNPSR1NPC1RAB9A
SCHEMBL31455238 0.79 TDP1 (0.49) MAPTTDP1MEN1KMT2APOLB
SCHEMBL12312164 0.78 ALDH1A1 (0.58) MAPTTDP1MEN1KMT2ANPSR1
SCHEMBL30092975 0.78 ALDH1A1 (0.58) MAPTTDP1MEN1KMT2ANPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250136570-A1 HDAC INHIBITORS AND THERAPEUTIC USE THEREOF TANGO THERAPEUTICS, INC. 2025-05-01 — — US disclosed
EP-4441033-A1 NOVEL HDAC INHIBITORS AND THERAPEUTIC USE THEREOF Tango Therapeutics, Inc. (US) 2024-10-09 — — EP disclosed
CN-118715206-A Novel HDAC inhibitors and therapeutic uses thereof 探戈医药股份有限公司 2024-09-27 — — CN disclosed
US-12043607-B2 HDAC inhibitors and therapeutic use thereof TANGO THERAPEUTICS, INC. (US) 2024-07-23 — — US disclosed
US-12043607-B2 HDAC inhibitors and therapeutic use thereof TANGO THERAPEUTICS, INC. (US) 2024-07-23 — — US disclosed
WO-2023102162-A1 TGONOVEL HDAC INHIBITORS AND THERAPEUTIC USE THEREOF TANGO THERAPEUTICS, INC. (US) 2023-06-08 — — WO disclosed
US-20230174501-A1 NOVEL HDAC INHIBITORS AND THERAPEUTIC USE THEREOF TANGO THERAPEUTICS, INC. 2023-06-08 — — US disclosed
US-20230174501-A1 NOVEL HDAC INHIBITORS AND THERAPEUTIC USE THEREOF TANGO THERAPEUTICS, INC. 2023-06-08 — — US disclosed
EP-0960103-A1 TERBENZIMIDAZOLES USEFUL FOR MEDICAL THERAPY (TOPOISOMERASE INHIBITORS) RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) 1999-12-01 — — EP disclosed
US-5948797-A ANTITUMOR AGENT RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) 1999-09-07 — — US disclosed
US-5807874-A ANTITUMOR AGENTS, ANTICARCINOGENIC AGENTS RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) 1998-09-15 — — US disclosed
WO-1998031673-A1 TERBENZIMIDAZOLES USEFUL FOR MEDICAL THERAPY (TOPOISOMERASE INHIBITORS) RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) 1998-07-23 — — WO disclosed
US-5770617-A Terbenzimidazoles useful as antifungal agents RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) 1998-06-23 — — US disclosed
US-5767142-A INHIBITION OF MAMMALIAN TUMOR CELL GROWTH RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) 1998-06-16 — — US disclosed
EP-0839140-A1 TRIBENZIMIDAZOLES USEFUL AS TOPOISOMERASE I INHIBITORS RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) 1998-05-06 — — EP disclosed
WO-1996036612-A1 TRIBENZIMIDAZOLES USEFUL AS TOPOISOMERASE I INHIBITORS RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) 1996-11-21 — — WO disclosed
US-4366319-A Process for preparing 5-(pyridinyl)benzoxazol-2(3H)-ones STERLING DRUG INC. (US) 1982-12-28 — — US disclosed
US-4310531-A 5-(Pyridinyl)-benzoxazol-2(3H)-ones and their use as cardiotonics STERLING DRUG INC. (US) 1982-01-12 — — US disclosed
US-4297362-A 4-(3,4-Diaminophenyl)pyridine or salts, and use thereof as cardiotonic STERLING DRUG INC. (US) 1981-10-27 — — US disclosed
US-4297363-A 2-Amino-3(4 or 5)-(pyridinyl)phenols and their use as cardiotonics STERLING DRUG INC. (US) 1981-10-27 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230174501-A1 NOVEL HDAC INHIBITORS AND THERAPEUTIC USE THEREOF HDAC1, HDAC7, HDAC5 MAPT 2684/4885TDP1 997/4885MEN1 4054/4885
US-20250136570-A1 HDAC INHIBITORS AND THERAPEUTIC USE THEREOF HDAC1, HDAC7, HDAC5 MAPT 2829/4885TDP1 846/4885MEN1 3551/4885
US-12043607-B2 HDAC inhibitors and therapeutic use thereof HDAC1, HDAC7, HDAC5 MAPT 2829/4885TDP1 846/4885MEN1 3551/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.